ViMRT
}  
 
Home   
< Docs   

 HIV mutation literature information.


  Virological outcomes with dolutegravir plus either lamivudine or two NRTIs as switch strategies: a multi-cohort study.
 PMID: 34849981       2022       The Journal of antimicrobial chemotherapy
Abstract: CONCLUSIONS: Lamivudine/dolutegravir maintenance DT showed similar efficacy to dolutegravir-based TT; however, past M184V/I may favour VF.
Abstract: Conversely, in the setting of pre-existing M184V/I, DT showed a trend to increased risk of VF (versus tenofovir-based TT, aHR = 137.50, 95% CI = 4.24-4464.06; versus abacavir-based TT, aHR = 33.88, 95% CI = 1.75-656.47).


  Prevalence of transmitted drug resistance among ART-naive HIV-infected individuals, Beijing, 2015-2018.
 PMID: 35092830       2022       Journal of global antimicrobial resistance
Abstract: The thymidine analogue mutations (TAMs) M41L/LM (4, 0.12%) and non-TAMs mutations M184V/MV/MI (8; 0.24%) were the primary NRTI-associated resistance mutations.


  Real-life experience with bictegravir/emtricitabine/tenofovir alafenamide in a large reference clinical centre.
 PMID: 35040990       2022       The Journal of antimicrobial chemotherapy
Abstract: In PLWH carrying an M184V/I substitution, OT RNA <50 copies/mL was 89.5% at M6.


  Comparing effectiveness of first-line antiretroviral therapy between peri-urban and rural clinics in KwaZulu-Natal, South Africa.
 PMID: 35023287       2022       HIV medicine
Abstract: K103N (59%) and M184V (52%) were the most common mutations, followed by V106M and K65R (31% each).


  Characterization of HIV-1 drug resistance among patients with failure of second-line combined antiretroviral therapy in central Ethiopia.
 PMID: 34622550       2022       HIV medicine
Abstract: Most common mutations were M184V (57.1%), Y188C (25.7%), M46I/L (25.7%) and V82A/M (25.7%).


  Brief Report: Bictegravir/Emtricitabine/Tenofovir Alafenamide Efficacy in Participants With Preexisting Primary Integrase Inhibitor Resistance Through 48 Weeks of Phase 3 Clinical Trials.
 PMID: 34897227       2022       Journal of acquired immune deficiency syndromes (1999)
Result: Notably, 4 had INSTI-R combined with NRTI-R substitutions relevant to the emtricitabine (FTC) or TAF components of the B/F/TAF regimen (M184V and/or K70E).
Table: M184V/I
Table: M184V


  Rising rates of recent preexposure prophylaxis exposure among men having sex with men newly diagnosed with HIV: antiviral resistance patterns and treatment outcomes.
 PMID: 34873084       2022       AIDS (London, England)
Abstract: M184V mutation was harboured more commonly in the recent PrEP use group (30% vs.
Abstract: DISCUSSION: Rapid PrEP intensification to ART allowed to achieve high rates of HIV viral suppression despite significant rates of M184V mutation harboured in those newly diagnosed with HIV and reporting recent PrEP exposure.
Result: Among those harbouring a Discussion: At least two-thirds of those carrying a M184V/I mutation in our cohort acquired HIV recently, with a large majority reporting sub-optimal PrEP adherence, irrespectively of the PrEP scheme adopted, confirming the trend observed previously in our cohort and in other reports.
Discussion: We confirm high rates of acquired viral resistance to emtricitabine, mostly in the form of M184V/I mutation, harboured in almost a third of these cases.


  Phase 2 Open-Label Study of Long-Term Safety, Tolerability, and Antiviral Activity of Rilpivirine in Antiretroviral-Naive Adolescents Living with HIV-1.
 PMID: 34871089       2022       Antimicrobial agents and chemotherapy
Result: The most frequent treatment-emergent NRTI RAM was M184V (4/15 patients [26.7%]).
Result: Three patients had both treatment-emergent RPV RAM E138K and NRTI RAM M184V at the last post-baseline time point with genotypic data.
Discussion: The most common treatment-emergent RPV and NRTI RAMs were E138K and M184V, respectively.


  Emergence of Resistance in HIV-1 Integrase with Dolutegravir Treatment in a Pediatric Population from the IMPAACT P1093 Study.
 PMID: 34694878       2022       Antimicrobial agents and chemotherapy
Result: Three participants had additional treatment-emergent resistance-associated reverse transcriptase substitutions of T215F/L, T215F/I/S/T and M230I/M, or M184V (n = 1 each) at PDVF.
Table: M184V


  Deep sequencing of HIV-1 reveals extensive subtype variation and drug resistance after failure of first-line antiretroviral regimens in Nigeria.
 PMID: 34741609       2022       The Journal of antimicrobial chemotherapy
Result: All participants with K65R also had
Discussion: Notably, all participants in the present analysis who had the K65R mutation also had M184I/V.
Discussion: This hypothesis was strengthened by the results of the NADIA trial, which showed that participants with K65R and M184V mutations at baseline were no more likely to fail a regimen containing tenofovir compared with zidovudine, when combined with lamivudine and either darunavir or dolutegravir.



Browser Board

 Co-occurred Entities




   Filtrator